Healthcare -
Medical - Instruments & Supplies - NYSE - US
$ 205.08
-1.09 %
$ 58.9 B
Market Cap
34.58
P/E
1. INTRINSIC VALUE
Balance Sheet
Becton, Dickinson and Company
| Current Assets | 10.5 B |
| Cash & Short-Term Investments | 2.3 B |
| Receivables | 3.03 B |
| Other Current Assets | 5.13 B |
| Non-Current Assets | 46.8 B |
| Long-Term Investments | 0 |
| PP&E | 6.82 B |
| Other Non-Current Assets | 40 B |
| Current Liabilities | 8.96 B |
| Accounts Payable | 1.9 B |
| Short-Term Debt | 2.17 B |
| Other Current Liabilities | 4.89 B |
| Non-Current Liabilities | 22.4 B |
| Long-Term Debt | 17.9 B |
| Other Non-Current Liabilities | 4.5 B |
EFFICIENCY
Earnings Waterfall
Becton, Dickinson and Company
| Revenue | 20.2 B |
| Cost Of Revenue | 11.1 B |
| Gross Profit | 9.12 B |
| Operating Expenses | 6.73 B |
| Operating Income | 2.4 B |
| Other Expenses | 692 M |
| Net Income | 1.7 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Becton, Dickinson and Company
| Net Income | 1.7 B |
| Depreciation & Amortization | 2.29 B |
| Capital Expenditures | -725 M |
| Stock-Based Compensation | 247 M |
| Change in Working Capital | 0 |
| Others | -183 M |
| Free Cash Flow | 3.12 B |
Wall Street Analysts Price Targets
Becton, Dickinson and Company
Wall Street analysts predict an average 1-year price target for BDX of $284 , with forecasts ranging from
a
low of
$270 to a high of $312 .
BDX Lowest Price Target
Wall Street Target
270 USD
31.66%
BDX Average Price Target
Wall Street Target
284 USD
38.34%
BDX Highest Price Target
Wall Street Target
312 USD
52.14%
4. DIVIDEND
ANALYSIS
0.46%
DIVIDEND YIELD
1.04 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Becton, Dickinson and Company
Sold
0-3 MONTHS
1.15 M USD 5
3-6 MONTHS
2.5 M USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
2.03 M USD 3
Bought
350 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BD to Announce Financial Results for its Second Quarter of Fiscal 2025
FRANKLIN LAKES, N.J. , April 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
prnewswire.com
- 1 week ago
Becton Dickinson in talks to divest life sciences unit, FT reports
Medical device maker Becton Dickinson has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific and Danaher , the Financial Times reported on Tuesday.
reuters.com
- 1 week ago
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.
seekingalpha.com
- 1 week ago
BD Named One of America's Most Innovative Companies by Fortune
FRANKLIN LAKES, N.J. , March 31, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% of companies overall.
prnewswire.com
- 1 week ago
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipeline. The firm is a proven dividend grower and cashflow generator with low debt/equity and investment-grade credit ratings.
seekingalpha.com
- 2 weeks ago
BD Names Gregory J. Hayes to Board of Directors
FRANKLIN LAKES, N.J. , March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J.
prnewswire.com
- 2 weeks ago
BDX Stock Declines Following Class I Classification for Alaris Recall
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
zacks.com
- 2 weeks ago
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
zacks.com
- 2 weeks ago
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
seekingalpha.com
- 3 weeks ago
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
- 3 weeks ago
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery
FRANKLIN LAKES, N.J. , March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.
prnewswire.com
- 3 weeks ago
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
- 3 weeks ago
8. Profile
Summary
Becton, Dickinson and Company BDX
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 58.9 B
Dividend Yield
0.46%
Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Contact
1 Becton Drive, Franklin Lakes, NJ, 07417-1880
https://www.bd.com
IPO
Date
Feb. 21, 1973
Employees
70000
Officers
Mr. Greg Rodetis
Senior Vice President, Treasurer & Head of Investor Relations
Ms. Denise Russell Fleming
Executive Vice President of Technology & Global Services and Chief Information Officer
Mr. Christopher J. DelOrefice CPA
Executive Vice President & Chief Financial Officer
Ms. Elizabeth McCombs
Executive Vice President & Chief Technology Officer
Ms. Pamela L. Spikner
Senior Vice President, Chief Accounting Officer & Controller
Mr. Thomas E. Polen Jr.
President, Chief Executive Officer & Chairman
Mr. Michael Garrison
Executive Vice President & President of Medical segment
Mr. Richard Byrd
Executive Vice President & President of Interventional Segment
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.
Senior Vice President & Chief Scientific Officer
Ms. Shana Carol Neal
Executive Vice President & Chief People Officer